American Board of Urology

      Certified: March 24, 1995

                        9/79-5/83       College of the Holy Cross

                                                Worcester, MA

            B.A. Chemistry

                        8/83-6/87       UMDNJ-Robert Wood Johnson Medical School

            Piscataway, NJ

                                                Doctor of Medicine

                   7/87-6/88       Kings County Hospital/SUNY-Downstate Medical Center

                                                Brooklyn, New York

                                                Internship

                        7/88-6/89       Kings County Hospital/SUNY-Downstate Medical Center

                                                Brooklyn, New York

                                                Resident in General Surgery

Harvard Program in Urology (Longwood Area)

                        7/89-9/93       Brigham and Women's Hospital, Beth Israel Hospital,

                                                The Children's Hospital, Dana-Farber Cancer Institute,

                                                West Roxbury Veteran's Hospital

                                                Boston, MA

Resident in Urological Surgery

                        7/90-6/91       Hartwell Harrison Urologic Research Laboratory

      Harvard Medical School, Boston, MA

                                                Urologic Research Fellow

                                      Northwest Hospital Center

                                          Greater Baltimore Medical Center

                                                Union Hospital of Cecil County

                                                St. Joseph Medical Center

                                                St. Agnes Medical Center

                                                Sinai Hospital of Baltimore

                          ICOS Corporation                                                          6/2003-Present

Sub-Investigator

A Phase II, randomized, double-blind, placebo-controlled study of the safety and efficacy of RTX topical solution in patients with interstitial cystitis.

                          Merck, Inc.                                                                     6/2003- Present

Principal Investigator

A double-blind, randomized, placebo-controlled, multicenter study to evaluate the effects of rofecoxib in decreasing the risk of prostate cancer (VIP study).

                          GlaxoSmithKline, Inc.                                                   6/2003-Present

Principal Investigator

A randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of dutasteride 0.5mg administered orally once daily for four years to reduce the risk of biopsy-detectable prostate cancer.

                          Novartis Pharmaceuticals                                               6/2003-Present

Principal Investigator

A double-blind, placebo-controlled study of the effect of zolendronic acid on bone mineral density in men receiving androgen-deprivation therapy for prostate cancer.

                          Pfizer, Inc.                                                                      6/2003-Present

Principal Investigator

A multicenter, randomized, parallel-group, double-blind, placebo-controlled, flexible dose escalation study to evaluate sexual and relationship satisfaction in the female partner of men with erectile dysfunction treated with Viagra(R) (sildenafil citrate) in the US.

                          GlaxoSmithKline, Inc.                                                   6/2003-Present

Principal Investigator

A randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy, safety and reliability of 10mg vardenafil administered for 12 weeks compared to placebo in subjects with erectile dysfunction and a demonstrated successful first response to 10mg vardenafil.

         Hoffman-La Roche, Inc.                                                 12/2002-Present

Principal Investigator

NN16378 open-label extension for treatment of incontinent patients who have completed an Ro115-1240 study.

         Hoffman-La Roche, Inc.                                                 5/2002-Present

Principal Investigator

Randomized, double-blind, placebo-controlled, dose finding study to evaluate the effects of a partial alpha adrenoceptor agonist, Ro115-1240, in women with stress urinary incontinence or mixed urinary incontinence.

         Eli Lilly                                                                                  2000-Present

Principal Investigator

Open Label. Long-term monitoring of safety in subjects treated with duloxetine for stress urinary incontinence.

                          GTx, Inc.                                                                        5/2002-5/2003

Principal Investigator

A Phase II, four-arm, dose-finding, randomized, placebo-controlled study to determine the safety and efficacy of 20mg, 40mg and 60mg toremifene in the prevention of osteoporosis of androgen deprivation.

                                 Medtronics, Inc.                                                             2-1/2004

                                       Principal Investigator

Medtronics Interstim(R) Patient Registry

                          Pharmacia & Upjohn                                                      1999-2003

Principal Investigator

A national Phase II trial of Interferon Alfa 2B (Intron A) plus BCG for treatment of superficial bladder cancer.

                          American Medical System/Pfizer                                   1996-2003

Principal Investigator

A multicenter prospective cohort study to evaluate the safety and effectiveness of the American Medical Systems' Ambicor inflatable penile prosthesis.

                          Pharmacia                                                                       5/2002-12/2002

Principal Investigator

A double-blind, placebo-controlled, randomized US study to evaluate the effect of tolterodine prolonged release on nocturia in patients with symptoms of overactive bladder (OAB).

                          Kyowa Pharmaceutical, Inc.                                          5/2002-12/2002

Principal Investigator

      A 6-week, double-blind, placebo-controlled randomized, parallel-group, multicenter, multidose study of the efficacy and safety of KW-7158 in patients with overactive bladder symptoms of increased urinary frequency, urgency and urge incontinence.

                          Health Decisions, Inc.                                                    2001-7/2003

Principal Investigator

A multicenter, pivotal Phase III, two-arm randomized placebo-controlled study to determine the chemoprevention efficacy and safety of 60mg daily of GTX-006 against high-grade prostate intraepithelial neoplasia (PIN).

                          Curon Corp, LLC                                                            7/2001-5/2002

Principal Investigator

Two-arm randomized, double-blind pilot herbal study for treatment of ureteral calculi.

                          Boehringer Ingelheim                                     4/2001-2/2002

Principal Investigator

A Phase II, double-blind, randomized, parallel-group design, multicenter study of FLOMAX(R) capsules, 0.4mg daily versus placebo in male patients with acute urinary retention related to benign prostatic hyperplasia.

                          Eli Lilly                                                                             9/2000-2/2002

Principal Investigator

A Phase III efficacy and safety of duloxetine compared with placebo in subjects with stress urinary incontinence.

                          Reprogenesis/Curtis                                                       2000-4/2002

Principal Investigator

A Phase II randomized, double-blind study comparing chondrogel (autologous chondrogel in alginate hydrogel) and alginate hydrogel for the treatment in women with stress urinary incontinence due to ISD.

                          TAP Holdings, Inc./Quintiles                                        1/2000-11/2001

Principal Investigator

A Phase II, 12-week safety and efficacy study of oral TAK-637 versus placebo in subjects with overactive bladder.

                          Pharmacia & Upjohn                                                      1/2000-10/2001

Principal Investigator

A patient acceptability study of a once-daily formulation of tolterodine.  A Phase IIIB open-label, single-arm trial in adult patients with overactive bladder and symptoms of urinary frequency/urgency and/or urge incontinence.

                          Bayer, Inc.                                                                      1/2000-8/2000

Principal Investigator

A randomized, open-label, comparative, experience trial of ciprofloxacin hydrochloride (250 to 500mg bid for 3-14 days) versus trimethoprim/sulfamethoxazole (160/800mg bid for 10-14 days) in the treatment of outpatient adults with lower urinary tract infections.  Protocol 100231.

                          TAP Pharmaceutical Inc.                                               2000-11/2001

Principal Investigator

A Phase II, 52-week extension study to evaluate long-term safety of oral TAK-637 in subjects with overactive bladder.

                          Reprogenesis                                                                  1999-2001

Principal Investigator

Protocol for the re-treatment with chondrogel (chondrocyte-alginate gel suspension) of patients enrolled in Reprogenesis' protocol 96-03.

                          Pharmacia & Upjohn                                                      1998-1999

Principle Investigator

A multicenter, pivotal Phase III two-arm, long-term safety and efficacy of tolteradine prolonged release capsules.

                          TAP Holdings, Inc.                                                        1998-2000

Principal Investigator

A Phase III long-term, open label, flexible dose, safety extension study of apomorphine SL tablets in a special population for the treatment of male erectile dysfunction..

                          TAP Holdings, Inc.                                                        1998-1999

Principal Investigator

A Phase III safety and efficacy study of two fixed doses of apomorphine SL tablets versus placebo in the treatment of male erectile dysfunction in patients with controlled diabetes.

                          Eli Lilly and Company                                                    1998-1999

Principal Investigator

Duloxetine versus placebo in the relief of stress urinary incontinence (Phase III)

                          Pharmacia & Upjohn                                                      1998-1999

Principal Investigator

Dose escalation study with tolterodine in patients with overactive bladder.  A single-blind study in patients with symptoms of overactive bladder including urinary urgency and frequency with or without urge incontinence.

                          Reprogenesis, Inc.                                                          1996-1999

Principal Investigator

Protocol for the clinical investigation of an autologous tissue implant for the treatment of urinary incontinence.

                          Medtronics, Inc.                                                             1996-1998

Principal Investigator

Randomized multicenter evaluation of the safety and effectiveness of the sacral nerve stimulation system for the treatment of urinary dysfunctional voiding patterns.

                          Upjohn Company                                                           1994-1996

Principal Investigator

Phase III study of oral bropiramine versus intravesical BCG in adult patients with BCG-naive bladder carcinoma in-situ.

R.W. Johnson Pharmaceuticals                                       1994-1995

Co-Investigator                                                       

Multicenter, double-blind, randomized study to compare the safety and efficacy of oral levofloxacin with that of ciprofloxacin HCL in the treatment of complicated urinary tract infections in adults.

                          Uromed Corporation                                                      1993-1998

Principal Investigator

Clinical investigation of a urethral occlusion device for the treatment of

stress urinary incontinence.

                          SmithKline Beecham Pharmaceuticals                           1993-1995

Co-Investigator

A one-year, multicenter, double-blind comparison of the effects of once-daily dosing with three dose levels of SK&F 105657 or placebo in the treatment of symptomatic BHP, with six-month untreated follow-up.

ALZA Corporation                                                         1993-1995

Co-Investigator

Acceptability of Testerderm testosterone, transdermal systems in private clinical practice.

            7/89-6/93                   Harvard Medical School

                                                Clinical Fellow in Surgery

            1/98-1/00                   Union Hospital of Cecil County

                                                Chief of Surgery

            7/99-Present                The Greater Baltimore Medical Center     

         Surgical Advisory Committee

            10/02-Present             Eli Lilly Scientific Advisory Board for Duloxdtine            

            7/03-Present               GlaxoSmithKline National Advisory Board for Avodart        

            1/4-Present                 The Greater Baltimore Medical Center Foundation Board

            4/3-5/92                     Laparoscopic Urologic Surgery   
                                                Office of Continuing Medical Education

                                                Harvard Medical School and Division of Urology

                                                Brigham and Women's Hospital

            4/1-4/93                     Pediatric Endourology and Laparoscopic Surgery 
                                                Office of Continuing Medical Education

                                                Harvard Medical School and Division of Urology

                                                The Children's Hospital

            6/24/95                      Management of Urinary Incontinence                                           

                                                Greater Baltimore Medical Center 

                                                Course Co-Director

            10/16-18/98               Advanced Management of Urinary Incontinence              

                                                Boca Raton, FL

         Course Co-Director

            4/25-26/03                 Management of Complex Urinary Incontinence

                                                and Pelvic Organ Prolapse

                                                Baltimore, MD

         Course Co-Director

        American College of Surgeons, Fellow

        Maryland Chapter, American College of Surgeons, Member

        American Urological Association, Member

        American Association of Clinical Urologists, Member

        Maryland Urological Association, Member

                                                American Association of Clinical Urologists

                                                 American Institute of Ultrasound in Medicine

                                                 American Medical Association

                                                 American College of Surgeons

                                                 American Urological Association

                 Baltimore County Medical Association

                 Federated Ambulatory Surgery Association

                 Maryland State Medical Society (Med Chi)

                 Maryland Urological Association

Gaylis FD, Ignatoff JM, Amling CL, Tutrone RF, Cosgrove DJ, Prostate Cancer in Men Using Testosterone Supplementation and Role of Physician Specialty in Diagnosis. (Submitted for publication 7/2003)

Dunn JS, Bent AE, Tutrone RF, Elkermann RM: Acute Renal Failure caused by Complete Bladder Eversion through a Vesicovaginal Fistula. Accepted by International Urogynecology.

Staskin DR, Bavendam T, Miller J, Davilla GW, Diokno A, Knapp P, Rapport S, Sand P, Sant G, Tutrone RF: Effectiveness of a Urinary Control Insert in the Management of Stress Urinary Incontinence: Early Results of a Multicenter Study. UROLOGY 47:629-636,1996.

Van den Abbeele AD, Tutrone RF, Berman RM, Baranowska-Kortzylewicz J, Barclay PD, Richie JP, Adelstein SJ, Kassis AI: Tumor-Targeting Potential of Radioiodinated Dododeox Yuridine in Bladder Cancer: Evaluation in Tumor-Bearing Rats. J. Nuclear Medicine, 37:315-320,1996.

Sand P, Bavendam T, Davilla G, Diokno A, Karram M, Knapp P, Miller J, Rappaport S, Sant G, Staskin D, Tutrone RF: The Effect of a Urinary Control Insert on Quality of Life in Incontinent Females. Obstetrics and Gynecology, 1996. International Urogynecology Journal 1999;10:100-105.

Tutrone RF, Ball RA, Ornitz DM, Leder PA, Richie JR: Benign Prostatic Hyperplasia in a Transgenic Mouse: A New Hormonally Sensitive Investigatory Mode. J. Urol., 149:633-639, 1993.

Tutrone RF, Capelouto CC, Kavoussi LR: The Role of Laparoscopy in the Management of Prostate Cancer. In Wein AF, Malkowicz SB eds. Controversies in the Prostate Cancer. Part 11. Philadelphia: CoMed Communications; 1993.

Tutrone RF, Ball RA, Ornitz D, Leder PA, Richie JP: Benign Prostatic Hyperplasia in a Transgenic Mouse: A New Hormonally Sensitive Model.  American College of Surgeons, Surgical Forum, XVII: 1991.

Van den Abbeele AD, Baranowska-Kortzylewicz J, Adelstein SJ, Carvalho PA, Tutrone RF, Richie JP, Wen PYC, Black PMcl, Mariani G, Kassis, AI: Diagnostic and Therapeutic Applications of Auger-Electron-Emitting 5-(¹²³/¹²⁵) Iodo-2'-Deoxyuridine in Cancer. Biophysical Aspects of Auger Processes, American Association of Physicists in Medicine. Symposium Series Number 8:372-295, 1992.

Tutrone RF, Bent A, McLennan M, Goldstein DS: Treatment of ISD Urinary Incontinence in Women Using Autologous Chondrocytes-Preliminary Results.  Hilton Head, SC, October 3-6, 1999.

McAleer H, Tutrone RF: Biofeedback/Electrical Stimulation Therapy in the Management of Urinary Incontinence in a Clinical Urology Practice. Annual Meeting AUA, Las Vegas, NV. April 23-28, 1995.

Duckett M, Goldstein DS, Goldstein RB, Shackleford N, Baker LS, Tutrone RF: The Use of Oral Trazodone for the Treatment of Venogenic Erectile Dysfunction. Annual Meeting AUA, Las Vegas, NV. April 23-28, 1995.

Capelouto CC, Raymond SA, Case CR, Tutrone RF, Richie JP, Vickers MA: Intraoperative Tumescence Monitoring During Radical Prostatectomy. Annual Meeting AUA, San Antonio, TX. May 15-20, 1993.

Tutrone RF, O'Donnell MA, Goldstein DS, Brodsky G, DeWolf WC, Richie JP: Intravesical Therapy with BCG for Transitional Cell Carcinoma of the Bladder in a Rat Model. Annual Meeting AUA, San Antonio, TX. May 15-20, 1993.

Tutrone RF, Goldstein DS, O'Donnell MA, Brodsky G, DeWolf WC, Richie JP: Intravesical Therapy with BCG for Transitional Cell Carcinoma of the Bladder in a Rat Model. Joint Annual Meeting Northeastern/New England Section AUA, Toronto, Ontario, Canada. September 13-16, 1992.

Tutrone RF, Ball RA, Ornitz D, Leder PA, Richie JP: Benign Prostatic Hyperplasia in a Transgenic Mouse: A New Hormonally Sensitive Investigatory Model. Annual Meeting AUA, Washington, D.C.  May 10-14, 1992.

Van den Abbeele AD, Tutrone RF, Berman RM, Baranowska-Kortylewicz J, Barclay PD, Richie JP, Adelstein SJ, Kassis AI: 5-(¹²³I/¹²⁵I) Iodo-2'-Deoxyuridine (*IUdR) as Diagnostic and Potential Therapeutic Agents for Bladder Cancer. Annual Radiation Research Society. Salt Lake City, UT. March 14-18, 1992.

Van den Abbeele AD, Barclay PD, Tutrone RF, Goldstein DS, Makrigiorgos GM, Berman RM, Weinberg DS, Richie JP, Adelstein SJ, Kassis, AI.: Radioiodinated IUdR (*IUdR) Uptake in Exfoliated Cells Obtained from Patient with Bladder Cancer: Implications for Diagnosis and Therapy. Annual Radiation Research Society, Salt Lake City, UT. March 14-18, 1992.

Tutrone RF, Ball RA, Ornitz D, Leder PA, Richie JP: Benign Prostatic Hyperplasia in a Transgenic Mouse: A New Hormonally Sensitive Mode. Annual Meeting New England Section AUA, Dixville Notch, NH. October 6-9, 1991.

Tutrone RF, Bauer SB, Peters CA, Mandell, J, Colodny AH, Retik AB: Physiologic Basis for Continence in the Mitrofanoff Principle. Annual Meeting AUA, Toronto, Canada. June 2-6, 1991.

Richie JP, Ball RA, Tutrone RF, Ornitz D, Leder PA: Int-2 Transgenic Mouse: New Investigatory Model for BPH. American Association of Genitourinary Surgeons, Annual Meeting, Naples, FL. April 4-6, 1991.

Tutrone RF, Bauer SB, Mandell J, Colodny AH, Retik AB: The Use of the Mitrofanoff Principle for Continent Urinary Diversion. Annual Meeting New England Section AUA, Edinburg, Scotland. October 21-27, 1990.

Tutrone RF, Laungani G: A New Method for Treatment of Intra-urethral Hair Growth Following Urethroplasty. Annual Valentine Resident Essay Meeting, New York Academy of Medicine. March 30, 1988.

Tutrone RF, Bailey RW: Laparoscopic Ureterolysis for Ovarian Vein Syndrome. Annual Meeting AUA, Las Vegas, Nevada. April 23-28, 1995.

Capelouto CC, Tutrone RF, Kavoussi LR: Laparoscopic Tissue Dissection Utilizing the Cavitational Ultrasonic Surgical Aspirator. Eleventh World Congress on Endourology, Florence, Italy. October 20-23, 1993.

Rosenberg M, Tutrone RF, Kavoussi L, Clayman R: Laparoscopic Radical Nephrectomy. Eleventh World Congress on Endourology, Florence, Italy. October 20-23, 1993.

Rosenberg MT, Tutrone RF, MacLeod SA, Clayman RV, Kavoussi LR: Laparoscopic Radical Nephrectomy. Video Urology '93 5^th World Congress, Orlando, Florida. June 24-27, 1993.

Rosenberg MT, Tutrone RF, MacLeod SA, Clayman RV, Kavoussi LR: Laparoscopic Radical Nephrectomy.  Annual Meeting AUA, San Antonio, TX. May 15-20, 1993.

Capelouto CC, O'Donnell MA, Tutrone RF, Kavoussi LR: Laparoscopic Tissue Dissection Utilizing the Cavitron Ultrasonic Surgical Aspirator. Annual Meeting AUA, San Antonio, TX. May 15-20, 1993.

Tutrone RF, Silverman SC, Kikinis R, Chernoff DM, Loughlin KR, Richie JP: Partial Nephrectomy with 3-D Image Enhancement. Countway Urology Grand Rounds, Harvard Medical School, Boston MA, October 3, 1992.

Ho, GT, Tutrone RF, Colodny A, Kavoussi LR: Endoscopic Hydrocele Ablation. Videourology '92, 4^th World Congress, Monte-Carlo.  October 1-3, 1992.

                        Baltimore Magazine, "Top Doc"                                              2000

                        Resident Essay Contest, First Prize                                         1991

                        AUA New England Section, Dixville Notch, NH

                        Basic Science Research, Second Prize                                     1991

                        Annual Resident Research Competition

                        Harvard/Countway Urology Rounds

                        Alpha Omega Alpha                                                                1987

                        Phi Beta Kappa                                                                       1983

                        Cum Laude- Holy Cross                                                          1983

                        Dean's List Four Consecutive Years                                       1983

                        Memorial Sloan-Kettering Cancer Center/                              1982

                         Roche Institute of Molecular Biology Research Scholarship

                        Memorial Sloan-Kettering Cancer Center/                              1981

                        Roche Institute of Molecular Biology Research Scholarship